Next, we evaluated the correlation between FGFR2/MET amplification and tumor mutational burden (TMB) status (≥10 mutations/mb vs. <10 mutations/mb), microsatellite instability (MSI) status (MSS vs. MSI high), and PD-L1 CPS score (CPS 0 vs. ≥1) (Figure 1E). The gene discussed is FGFR2; the disease is neoplasm.